You are here: Industry Insights > NIAID

News List

Intravacc gets US NIAID contract to develop enterovirus D68 vaccine expresspharma
September 17, 2020
EV D68 is a respiratory virus that can cause childhood paralysis, acute flaccid myelitis.
Baricitinib in combination with remdesivir reduces recovery time in hospitalised COVID-19 patients: Study expresspharma
September 16, 2020
Data from the Adaptive COVID-19 Treatment Trial (ACTT-2) revealed an approximately one-day reduction in median recovery time for the overall patient population.
Versatope Awarded Grant for Novel C. diff Vaccine americanpharmaceuticalreview
September 15, 2020
Versatope Therapeutics has been awarded a Phase 1 Small Business and Innovation Award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to develop a novel vaccine ...
Eveliqure Announces NIAID Contract to Study Shigella, ETEC Vaccine Candidate americanpharmaceuticalreview
September 14, 2020
Eveliqure Biotechnologies GmbH announced the award of a US government contract from the National Institute of Allergy and Infectious Diseases (NIAID), contract #75N93020C00048 with the intent to fund the development of its vaccine candidate, ShigETEC ...
American Gene Technologies gets US FDA nod for Phase 1 clinical trial of potential HIV cure expresspharma
August 13, 2020
AGT’s Phase 1 trial will investigate the safety of AGT103-T, a single-dose, lentiviral vector-based gene therapy, and measure key biomarkers as well as explore surrogate markers of efficacy.
SRI Biosciences Awarded $100M NIAID Contract contractpharma
August 06, 2020
Seven-year contract to support the research and development of radiation/nuclear medical countermeasures.
Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery worldpharmanews
May 28, 2020
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in The New England Journal of Medicine.
Gilead announces primary endpoints met in Phase III remdesivir trial europeanpharmaceuticalreview
April 30, 2020
Gilead has said that topline results for clinical recovery have been demonstrated in a Phase III trial of remdesivir, tested in COVID-19 patients.
NIAID strategic plan for COVID-19 focuses on developing assays, therapeutics and vaccines europeanpharmaceuticalreview
April 30, 2020
The US National Institute of Allergy and Infectious Diseases (NIAID) has revealed its research priorities relating to COVID-19, including supporting the development and testing of potential therapeutics and vaccines.
RedHill Biopharma partners with NIAID for potential Covid-19 drug pharmaceutical-technology
April 22, 2020
Israel-based RedHill Biopharma has partnered with the US National Institute of Allergy and Infectious Diseases (NIAID) to study its RHB-107 (upamostat, WX-671) drug candidate in non-clinical tests for the treatment of Covid-19.

Previous page 1 2 3 4 5 Next page